Current Direction details

The purpose of this Direction is to prohibit a person from using a point of care serological (blood) test or a point of care antigen based or nucleic acid based (upper or lower respiratory tract or oropharyngeal specimen) test (including an assay or device) as an acute illness diagnostic tool for COVID-19, as their use may adversely affect the prevention, control and abatement of the serious public health risk present by COVID-19.

This direction does not apply to employees of SA Pathology or the Department of Health and Wellbeing.

This direction may be cited as the Emergency Management (Prohibition of Certain Point of Care Tests No 2) (COVID-19) Direction 2020.

It came into effect at 9:00 am on 16 March 2021 and revokes the Emergency Management (Prohibition of Point of Care Serology Tests) (COVID-19) Direction 2021.

Emergency Management (Prohibition of Certain Point of Care Tests No 2) (COVID-19) Direction 2020 (PDF, 52.6 KB) - 16 March 2021

Emergency Management (Prohibition of Certain Point of Care Tests No 2) (COVID-19) Direction 2020 (RTF, 89.7 KB) - 16 March 2021

Page last updated: 16 March 2021